Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | CLK3 | P49761 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GUSB | P08236 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1462822 | 0.90 | ORAI1 (0.42) | ORAI1MAPTLRRK2PTGESCYP2C9 | |
| SCHEMBL1459966 | 0.83 | ORAI1 (0.51) | ORAI1MAPTLRRK2PTGESCYP2C9 | |
| Cyanide SCHEMBL27862347 | 0.83 | ORAI1 (0.49) | ORAI1PTGESCYP2C9CLK2CLK3 | |
| SCHEMBL1460101 | 0.74 | ORAI1 (0.59) | ORAI1PTGESCYP2C9 | |
| SCHEMBL1462823 | 0.73 | ORAI1 (0.41) | ORAI1MAPTPTGESCYP2C9METAP2 | |
| SCHEMBL1459911 | 0.73 | ORAI1 (0.58) | ORAI1PTGESCYP2C9 | |
| SCHEMBL1460901 | 0.73 | ORAI1 (0.47) | ORAI1PTGESCYP2C9 | |
| SCHEMBL1459495 | 0.73 | ORAI1 (0.44) | ORAI1PTGESCYP2C9 | |
| SCHEMBL12825958 | 0.72 | ORAI1 (0.57) | ORAI1MAPTPTGESCYP2C9KDM4E | |
| SCHEMBL1464317 | 0.72 | ORAI1 (0.55) | ORAI1PTGESCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | ORAI1 1/4885MAPT 2068/4885RPS6KA3 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.